نمایش پرونده ساده آیتم

dc.contributor.authorBarzegar-Jalali, M
dc.contributor.authorMohammadi, K
dc.contributor.authorMohammadi, G
dc.contributor.authorValizadeh, H
dc.contributor.authorBarzegar-Jalali, A
dc.contributor.authorAdibkia, K
dc.contributor.authorNokhodchi, A
dc.date.accessioned2018-08-26T08:06:00Z
dc.date.available2018-08-26T08:06:00Z
dc.date.issued2012
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/49933
dc.description.abstractPurpose. Drug release from nanosystems at the sites of either absorption or effect biophase is a major determinant of its biological action. Thus, in vitro drug release is of paramount importance in gaining insight for the systems performance in vivo. Methods. A novel in vitro in vivo correlation, IVIVC, model denoted as double reciprocal area method was presented and applied to 19 drugs from 55 nano formulations with total 336 data, gathered from literature. Results. The proposed model correlated the in vitro with in vivo parameters with overall error of 12.4 +/- 3.9%. Also the trained version of the model predicted the test formulations with overall error of 15.8 +/- 3.7% indicating the suitability of the approach. A theoretical justification was provided for the model considering the unified classical release laws. Conclusion. The model does not necessitate bolus intravenous drug data and seems to be suitable for IVIVC of drugs with release rate-limited absorption.
dc.language.isoEnglish
dc.relation.ispartofJOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
dc.titleA Correlative Model to Predict In Vivo AUC for Nanosystem Drug Delivery with Release Rate-Limited Absorption
dc.typeArticle
dc.citation.volume15
dc.citation.issue4
dc.citation.spage583
dc.citation.epage591
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.18433/J3NP5N


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم